Ductus arteriosus

Global Cardiovascular Partnering Report 2014-2021: Deal Trends, Players and Financials of 850 Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Health, Cardiology, Shortness of breath, Cardiogenic shock, Research, Technology, Peripheral artery disease, Abdominal aortic aneurysm, Heart failure, Birth defect, Marfan syndrome, Confidentiality, Congestion, Myocardial infarction, Long QT syndrome, Ductus arteriosus, Intellectual property, Fatigue, Varicose veins, Intermittency, Finance, Atrial fibrillation, Congenital heart defect, Syndrome, Ventricular tachycardia, Ownership, Cardiovascular disease, Aortic stenosis, Circulatory system, Peripheral, Players, Coronary artery disease, Ventricular fibrillation, Chest pain, Supraventricular tachycardia, Valvular heart disease, Video game, Pharmaceutical industry, Lease, Sales, Petroleum, Property management, Practice of law, Restenosis, Thrombus, Hypertension, Hypercholesterolemia, Cardiomyopathy, Arrhythmia, Global, Atherosclerosis, Angina

The "Global Cardiovascular Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cardiovascular Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals.
  • The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.
  • In Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials, the available deals are listed by:
    Analyzing actual contract agreements allows assessment of the following:
    What are the precise rights granted or optioned?

Le Bonheur Children's Hospital Implants First Commercial FDA-Approved Transcatheter Device for PDA Patients

Retrieved on: 
Thursday, February 7, 2019
Le bonheur, Le Bonheur Children's Hospital, Patent ductus arteriosus, Bonheur, Ductus arteriosus, Memphis, Tennessee, Cities in the United States

MEMPHIS, Tenn., Feb. 7, 2019 /PRNewswire/ --Le Bonheur Children's Hospital cardiologists have implanted the world's first commercially-approved medical device for transcatheter patent ductus arteriosus closure in the tiniest babies (weighing as little as two pounds).

Key Points: 
  • MEMPHIS, Tenn., Feb. 7, 2019 /PRNewswire/ --Le Bonheur Children's Hospital cardiologists have implanted the world's first commercially-approved medical device for transcatheter patent ductus arteriosus closure in the tiniest babies (weighing as little as two pounds).
  • Le Bonheur enrolled more neonates than any other center in the study.
  • Le Bonheur Children's Hospital in Memphis, Tenn., treats children each year through community programs, regional clinics and a 255 bed state-of-the-art hospital.
  • Nationally recognized, Le Bonheur is ranked by U.S. News & World Report as a Best Children's Hospital.